You are here: Industry Insights > SARS-CoV-2

News List

MERS vaccine shows promise in clinical trial, say researchers europeanpharmaceuticalreview
April 30, 2020
A clinical trial to study a MERS vaccine has demonstrated success, say researchers, suggesting their technology could be repurposed to halt the spread of COVID-19.
Merck signs Covid-19 research alliance with ISB pharmaceutical-technology
April 30, 2020
Merck (MSD) has entered a research collaboration with the Institute for Systems Biology (ISB) to study molecular mechanisms of SARS-CoV-2 and Covid-19 infection.
Pneumagen reports positive lab data of Covid-19 drug candidates pharmaceutical-technology
April 30, 2020
University of St Andrews spin-out Pneumagen has reported positive findings from three in-vitro studies of Neumifil and other multivalent carbohydrate binding modules (mCBMs) to prevent infection by coronaviruses, including SARS-CoV-2.
Pneumagen Announces Results from COVID-19 Infection Prevention Study americanpharmaceuticalreview
April 29, 2020
Pneumagen announced results from three separate in vitro studies into preventing coronavirus infections including SARS-CoV-2 infection.
Merck and Institute for Systems Biology Enter COVID-19 Collaboration contractpharma
April 29, 2020
To define molecular mechanisms of SARS-CoV-2 infection and identify potential prognostic biomarkers.
Genalyte Launches High-Speed COVID-19 Antibody Test contractpharma
April 29, 2020
First instrument-based, rapid test uses multi-antigen approach; U.S. FDA EUA submitted.
Marinomed receives FFG funding to research SARS-CoV-2 therapy based on carragelose expresspharma
April 29, 2020
Available clinical data show that Carragelose binds previously known coronaviruses and other viruses that trigger respiratory infections.
AGC Biologics, AdaptVac Partner to Develop COVID-19 Vaccine contractpharma
April 28, 2020
Will leverage AdaptVac's Virus-Like Particle (VLP) technology that could provide a solution to protect against new SARS-CoV-2 infections.
Romark Initiates Trials of NT-300 for COVID-19 Prevention contractpharma
April 28, 2020
In cell cultures, the active ingredient in NT-300, nitazoxanide, inhibits replication of a broad range of respiratory viruses, including SARS-CoV-2.
Immunic Reports IMU-838 Demonstrates Preclinical Activity Against SARS-CoV-2 americanpharmaceuticalreview
April 24, 2020
Immunic reported that its lead asset, IMU-838, a selective oral DHODH inhibitor, has successfully demonstrated preclinical activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 61 62 Next page